Brooks, Alan D <br/><br/>
The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.  [electronic resource] 

 -  Annals of the New York Academy of Sciences  Nov 2005 
 - 160-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>0077-8923 
<br/><br/><label>Standard No.: </label>10.1196/annals.1339.042  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Apoptosis<br/>Apoptosis Regulatory Proteins--metabolism<br/>Boronic Acids--pharmacology<br/>Bortezomib<br/>Cell Line, Tumor<br/>Dose-Response Relationship, Drug<br/>Humans<br/>Ligands<br/>Membrane Glycoproteins--metabolism<br/>Neoplasms--metabolism<br/>Proteasome Inhibitors<br/>Pyrazines--pharmacology<br/>TNF-Related Apoptosis-Inducing Ligand<br/>Tumor Necrosis Factor-alpha--metabolism<br/>Tumor Suppressor Protein p53--metabolism<br/>bcl-2-Associated X Protein--metabolism